|
January 20, 2006 Categories: Uncategorized Posted by admin
A proxy advisory firm is recommending Guidant Corp. shareholders reject Johnson & Johnson’s latest buyout proposal, a move that comes as J&J weighs whether to sweeten its offer for the medical device maker once again to trump Guidant’s favored suitor of the moment, Boston Scientific Corp.
The Massachusetts company owes its current front-runner status in part to Abbott Laboratories Inc., a third-party player whose offer of cash and other assistance to help Boston Scientific go after Guidant is fueling speculation that the new allies could themselves become merger partners someday.
Full news
|
|
